Leerink Partnrs Has Positive Outlook for BBIO Q1 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO) – Research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for BridgeBio Pharma in a research note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.69) per share for the quarter, up from their previous estimate of ($0.72). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.86) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.15) EPS and FY2026 earnings at ($1.58) EPS.

A number of other equities analysts have also issued reports on BBIO. Scotiabank upped their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price target on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a report on Monday, March 24th. Cantor Fitzgerald reissued an “overweight” rating and set a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. HC Wainwright boosted their target price on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Finally, Citigroup increased their price target on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $53.00.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO opened at $33.87 on Friday. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of -11.88 and a beta of 1.08. BridgeBio Pharma has a one year low of $21.62 and a one year high of $39.47. The business’s 50-day simple moving average is $33.79 and its 200 day simple moving average is $30.11.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to the consensus estimate of $4.04 million.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in BridgeBio Pharma by 71.0% in the first quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after purchasing an additional 382 shares during the period. Steward Partners Investment Advisory LLC lifted its holdings in BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock valued at $28,000 after acquiring an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of BridgeBio Pharma during the 4th quarter valued at about $41,000. Sterling Capital Management LLC grew its stake in shares of BridgeBio Pharma by 554.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock worth $49,000 after purchasing an additional 1,514 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in BridgeBio Pharma during the fourth quarter valued at approximately $109,000. 99.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $36.87, for a total value of $2,765,250.00. Following the sale, the chief executive officer now owns 4,948,447 shares in the company, valued at approximately $182,449,240.89. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the transaction, the insider now owns 19,260,971 shares of the company’s stock, valued at approximately $634,841,604.16. This represents a 23.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,694,739 shares of company stock worth $327,308,651 over the last ninety days. Company insiders own 24.66% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.